Effects of behavioral sleep extension on Alzheimers disease relevant blood biomarkers and cognitive performance

行为睡眠延长对阿尔茨海默病相关血液生物标志物和认知能力的影响

• 批准号: 10288146
• 负责人: Kelly Glazer Baron
• 金额: $ 33.78万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-27 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10288146
• 关键词: Acute; Adolescent; Adult; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Ambulatory Blood Pressure Monitoring; Amino Acids; Area; Behavioral; Biochemical Pathway; Biological; Biological Assay; Biological Markers; Blood; Blood Pressure; Blood specimen; Body mass index; Brain; Cardiometabolic Disease; Clinical Trials; Cognition; Cognitive; Consensus; Control Groups; Data; Dementia; Development; Diagnostic; Diet; Disease; Drowsiness; Elderly; Epidemiology; Future; Goals; Grant; Health; Health education; Hour; Hypertension; Impact evaluation; Impaired cognition; Individual; Inflammation; Intervention; Laboratories; Lead; Learning; Link; Literature; Maintenance; Measures; Mediator of activation protein; Metabolic; National Health Interview Survey; Neurodegenerative Disorders; Outcome; Outcome Measure; Parents; Patient Self-Report; Performance; Physical activity; Physiological; Population; Populations at Risk; Quality of life; Randomized; Randomized Controlled Trials; Recommendation; Reporting; Research; Risk; Risk Factors; Sleep; Sleep Disorders; Testing; Time; Vascular Dementia; Visuospatial; acylcarnitine; base; behavioral phenotyping; biomarker identification; biomarker panel; biomarker performance; cardiometabolic risk; cardiometabolism; cognitive change; cognitive performance; cognitive testing; comparison intervention; dementia risk; design; disorder risk; epidemiology study; experimental study; follow-up; glycemic control; improved; improvement on sleep; metabolomics; middle age; mild cognitive impairment; modifiable risk; novel; pre-clinical; predictive marker; prehypertension; primary outcome; processing speed; psychologic; public health relevance; response; response biomarker; secondary outcome; small molecule; tool; vigilance; young adult

PROJECT SUMMARY/ABSTRACT Decades of experimental and epidemiologic research link short sleep duration to adverse cardiometabolic health. Furthermore, emerging research points to direct biological mechanisms linking short sleep duration to cognitive decline and Alzheimer’s disease. Despite decades documenting the deleterious effects of short sleep duration, few studies have sought to improve risk or modify Alzheimer’s disease trajectories by extending sleep. Sleep extension interventions hold promise to improve cardiometabolic disease (CMD) risk, cognition and quality of life. To date, several small studies have demonstrated short term improvements in sleep and CMD risk such as blood pressure and glycemic control. However, existing studies in adults have not addressed whether sleep extension interventions impact cognitive performance and biomarkers of Alzheimer’s Disease risk. The goal of this application is to extend the aims of our parent study to include an examination of the impact of our randomized behavioral sleep extension intervention on Alzheimer’s related biomarkers (blood metabolomics) and cognitive performance measures. In our parent study, we are conducting a randomized controlled trial to test our behavioral sleep extension intervention compared to a health education control group on sleep and CMD risk among adults with prehypertension/stage I hypertension. The 12-month study includes an intervention period (weeks 1-8, weekly intervention), maintenance period (months 2-6, monthly intervention) and follow-up period (no intervention). The primary outcome for the parent study is sleep duration and the main secondary outcome is 24-h ambulatory blood pressure monitoring, which allows us to evaluate both daytime and nighttime blood pressures. The design of this parent study will allow us to examine the acute (8 week) and sustained (12 month) changes in sleep duration, BP and important psychological, behavioral and physiological mediators including self-reported sleepiness, BMI, diet, physical activity, glycemic control and inflammation. The receipt of this Alzheimer’s disease supplement will allow us to extend the scope of our parent study to examine the effects of our sleep extension intervention on blood biomarkers and cognitive performance. Successful completion of this study will provide critical information about the impact of behavioral sleep extension on important measures of health and quality of life needed to incorporate sleep extension into CMD, and potentially Alzheimer’s disease risk interventions. Completion of this supplement will identify potential biochemical pathways and behavioral phenotypes that respond to sleep extension. Identification of these biological and behavioral markers of response to sleep extension has the potential to lead to identification of biomarkers and novel targets to reduce Alzheimer’s Disease risk.

项目摘要/摘要 数十年的实验和流行病学研究表明，睡眠时间短与心脏代谢不良有关 健康。此外，新出现的研究指出了将睡眠时间短与 认知功能减退和阿尔茨海默病。尽管几十年来记录了睡眠不足的有害影响 持续时间，很少有研究试图通过延长阿尔茨海默病的风险或改变阿尔茨海默病的轨迹 睡吧。延长睡眠干预有望改善心脏代谢性疾病(CMD)的风险和认知 和生活质量。到目前为止，几项小规模的研究已经证明了睡眠和 CMD风险，如血压和血糖控制。然而，现有的成人研究还没有解决 睡眠延长干预是否影响阿尔茨海默病患者的认知能力和生物标志物 风险。这项申请的目标是扩展我们的家长研究的目标，包括考试 我们的随机行为延长睡眠干预对阿尔茨海默病相关患者的影响 生物标记物(血液代谢组学)和认知表现测量。在我们的父母研究中，我们 进行一项随机对照试验，以测试我们的行为睡眠延长干预与 高血压前期/I期成人睡眠与CMD风险健康教育对照组 高血压。这项为期12个月的研究包括干预期(1-8周，每周干预)， 维持期(2-6个月，每月干预)和随访期(不干预)。初级阶段 母研究的结果是睡眠时间，主要的次要结果是24小时动态血液 血压监测，使我们能够评估白天和夜间的血压。一种新的设计 这项家长研究将使我们能够检查睡眠的剧烈(8周)和持续(12个月)变化 持续时间、血压和重要的心理、行为和生理调节因素，包括自我报告 嗜睡、体重指数、饮食、体力活动、血糖控制和炎症。阿尔茨海默氏症的收据 疾病补充剂将允许我们扩大父母研究的范围，以检查我们的 睡眠延长干预对血液生物标记物和认知表现的影响。成功完成 这项研究将提供有关行为睡眠时间延长对重要的 将睡眠延长纳入CMD所需的健康和生活质量衡量标准，并可能 阿尔茨海默病风险干预。完成这一补充将确定潜在的生化 对睡眠延长作出反应的路径和行为表型。这些生物和生物的鉴定 睡眠延长反应的行为标记物有可能导致识别生物标记物和 降低阿尔茨海默病风险的新目标。